MX381508B - Composición farmacéutica inyectable que incluye trabectedina para uso gastrointestinal externo y método para la fabricación de la misma. - Google Patents

Composición farmacéutica inyectable que incluye trabectedina para uso gastrointestinal externo y método para la fabricación de la misma.

Info

Publication number
MX381508B
MX381508B MX2018009088A MX2018009088A MX381508B MX 381508 B MX381508 B MX 381508B MX 2018009088 A MX2018009088 A MX 2018009088A MX 2018009088 A MX2018009088 A MX 2018009088A MX 381508 B MX381508 B MX 381508B
Authority
MX
Mexico
Prior art keywords
trabectedin
pharmaceutical composition
composition including
injectable pharmaceutical
manufacturing same
Prior art date
Application number
MX2018009088A
Other languages
English (en)
Other versions
MX2018009088A (es
Inventor
Chen Xu
Kai Liu
Likun Wang
Qiong Sun
Rong Yin
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018009088A publication Critical patent/MX2018009088A/es
Publication of MX381508B publication Critical patent/MX381508B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica inyectable que incluye trabectedina para uso gastrointestinal externo y al método para la fabricación de la misma. Específicamente, la composición contiene trabectedina y un primer excipiente, el primer excipiente siendo seleccionado de entre uno, o más, de monosacáridos y polioles. La preparación en la presente invención tiene una calidad estable y puede ser aplicada a una producción en masa.
MX2018009088A 2016-02-04 2017-01-23 Composición farmacéutica inyectable que incluye trabectedina para uso gastrointestinal externo y método para la fabricación de la misma. MX381508B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610081052 2016-02-04
PCT/CN2017/072220 WO2017133544A1 (zh) 2016-02-04 2017-01-23 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
MX2018009088A MX2018009088A (es) 2018-09-03
MX381508B true MX381508B (es) 2025-03-12

Family

ID=59499346

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009088A MX381508B (es) 2016-02-04 2017-01-23 Composición farmacéutica inyectable que incluye trabectedina para uso gastrointestinal externo y método para la fabricación de la misma.

Country Status (14)

Country Link
US (1) US10610529B2 (es)
EP (1) EP3412293A4 (es)
JP (1) JP2019504061A (es)
KR (1) KR20180103965A (es)
CN (1) CN107427512B (es)
AU (1) AU2017215603A1 (es)
BR (1) BR112018015118A2 (es)
CA (1) CA3011527A1 (es)
HK (1) HK1244713A1 (es)
MX (1) MX381508B (es)
RU (1) RU2738741C2 (es)
TW (1) TWI720117B (es)
WO (1) WO2017133544A1 (es)
ZA (1) ZA201804964B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108276408B (zh) * 2018-04-19 2020-09-29 上海皓元医药股份有限公司 一种曲贝替定的中间体及其制备方法和用途
US20210169873A1 (en) * 2019-10-21 2021-06-10 RK Pharma Solutions LLC Storage-stable ready-to-use injectable formulations of Trabectedin
CA3176956A1 (en) 2020-04-15 2021-10-21 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid
US12303506B2 (en) * 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy

Also Published As

Publication number Publication date
MX2018009088A (es) 2018-09-03
RU2018128913A (ru) 2020-03-04
BR112018015118A2 (pt) 2018-12-18
EP3412293A1 (en) 2018-12-12
CN107427512B (zh) 2021-10-08
WO2017133544A1 (zh) 2017-08-10
KR20180103965A (ko) 2018-09-19
JP2019504061A (ja) 2019-02-14
TW201728327A (zh) 2017-08-16
ZA201804964B (en) 2019-12-18
RU2018128913A3 (es) 2020-06-23
AU2017215603A1 (en) 2018-08-09
US10610529B2 (en) 2020-04-07
CN107427512A (zh) 2017-12-01
CA3011527A1 (en) 2017-08-10
EP3412293A4 (en) 2019-10-16
TWI720117B (zh) 2021-03-01
HK1244713A1 (zh) 2018-08-17
RU2738741C2 (ru) 2020-12-16
US20190030028A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX2018003476A (es) Ceramicas y compuestos de sinterizacion en frio.
CL2019000325A1 (es) Composicion farmaceutica que comprende un compuesto derivado de piridona policiclico sustituido o su sal, que tiene actividad inhibidora de la endonucleasa dependiente de cap; cristal; y composicion farmaceutica que comprende dicho cristal.
EP3835296A4 (en) KETOAMIDE COMPOUND AND PRODUCTION PROCESS, PHARMACEUTICAL COMPOSITION AND USE THEREOF
DK3804715T3 (da) Farmaceutisk kombination, sammensætning og forbindelsespræparat omfattende glucokinase-aktivator og dpp-iv-inhibitor, og fremgangsmåde til fremstilling og anvendelser deraf
JOP20200110B1 (ar) إينانشيوميرات من الثيازولات المستبدلة كمركبات مضادة للفيروسات
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
UY32388A (es) Composicion farmaceutica sólida que comprende amlodipina y losartan con estabilidad mejorada
ZA201803114B (en) High modulus glass fibre composition, and glass fibre and composite material thereof
MX374012B (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.
MX2019011759A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando el mismo.
AR112226A1 (es) Comprimidos preparados por compresión
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
BR112017021126A2 (pt) composição de lignina ativada, método para a sua produção e utilização
SI3424889T1 (sl) Sestavek steklenih vlaken z visokim modulom in stekleno vlakno ter kompozitni material iz njega
ES2896048T8 (es) Composición de frita de vidrio y tinta cerámica de inyección de chorro que comprende la misma
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
MX2017007699A (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
MX2016007878A (es) Composicion farmaceutica que comprende adalimumab.
WO2015092012A3 (fr) Procédé de fabrication d'un composant horloger
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
MX2018009088A (es) Composicion farmaceutica inyectable que incluye trabectedina para uso gastrointestinal externo y metodo para la fabricacion de la misma.
MX2019011931A (es) Formas cristalinas de (s)-afoxolaner.
EP3626271A4 (en) SELF-SYSTEMULABLE COMPOSITION, MANUFACTURING METHODS FOR IT, NANOEMULSION AND MANUFACTURING METHODS FOR IT
MX389026B (es) Una composicion farmaceutica y el uso de la misma.